Tumor-intrinsic PIK3CA represses tumor immunogenicity in a model of pancreatic cancer
Open accessThe DOI matches its Crossref record; 70 of the 71 references it cites were found in a registry or an index.
Abstract
The presence of tumor-infiltrating T cells is associated with favorable patient outcomes, yet most pancreatic cancers are immunologically silent and resistant to currently available immunotherapies. Here we show using a syngeneic orthotopic implantation model of pancreatic cancer that Pik3ca regulates tumor immunogenicity. Genetic silencing of Pik3ca in KrasG12D/Trp53R172H-driven pancreatic tumors resulted in infiltration of T cells, complete tumor regression, and 100% survival of immunocompetent host mice. By contrast, Pik3ca-null tumors implanted in T cell-deficient mice progressed and killed all of the animals. Adoptive transfer of tumor antigen-experienced T cells eliminated Pik3ca-null tumors in immunodeficient mice. Loss of PIK3CA or inhibition of its effector, AKT, increased the expression of MHC Class I and CD80 on tumor cells. These changes contributed to the increased susceptibility of Pik3ca-null tumors to T cell surveillance. Our results indicate that tumor cell PIK3CA-AKT signaling limits T cell recognition and clearance of pancreatic cancer cells. Strategies that target this pathway may yield an effective immunotherapy for this cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“PI3K and AKT1 inhibitors have also been shown to boost IFNG-driven class I and class II antigen presentation as a mechanism of cancer-cell-dependent immunostimulation (Chandrasekaran et al., 2019; Marijt et al., 2019; Sivaram et al., 2019)”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Sivaram et al., 2019
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dranoff, G., Jaffee, E., Lazenby, A., Golumbek, P., Levitsky, H., Brose, K., Jackson, V, Hamada, H., Pardoll, D., & Mulligan, R. C. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.8.3539 · Cited by 2,818
Hingorani, S. R., Wang, L., Multani, A. S., Combs, C., Deramaudt, T. B., Hruban, R. H., Rustgi, A. K., Chang, S., & Tuveson, D. A. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.04.023 · Cited by 2,609
Targeting PI3K signalling in cancer: opportunities, challenges and limitations
Engelman, J. A. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2664 · Cited by 2,445
Regulation and Function of the PD-L1 Checkpoint
Sun, C., Mezzadra, R., & Schumacher, T. N. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.014 · Cited by 2,193
PI3K and cancer: lessons, challenges and opportunities
Fruman, D. A., & Rommel, C. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4204 · Cited by 1,709
CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans
Beatty, G. L., Chiorean, E. G., Fishman, M. P., Saboury, B., Teitelbaum, U. R., Sun, W., Huhn, R. D., Song, W., Li, D., Sharp, L. L., et al. (2011) · Science · doi:10.1126/science.1198443 · Cited by 1,672
CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes
Janssen, E. M., Lemmens, E. E., Wolfe, T., Christen, U., von Herrath, M. G., & Schoenberger, S. P. (2003) · Nature · doi:10.1038/nature01441 · Cited by 1,635 · cited 1×
“CD4+ T cells may also acquire cytotoxic activity in vivo as seen in some melanomas (47, 48), and can play a role in generating and maintaining memory CD8+ T cells (49, 50).”
BackgroundRequirement for CD4 T Cell Help in Generating Functional CD8 T Cell Memory
Shedlock, D. J., & Shen, H. (2003) · Science · doi:10.1126/science.1082305 · Cited by 1,460
Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer
Initiative, A. P. C. G., Balachandran, V. P., Łuksza, M., Zhao, J. N., Makarov, V., Moral, J. A., Remark, R., Herbst, B., Askan, G., Bhanot, U., et al. (2017) · Nature · doi:10.1038/nature24462 · Cited by 1,191
PI3Kγ is a molecular switch that controls immune suppression
Kaneda, M. M., Messer, K. S., Ralainirina, N., Li, H., Leem, C. J., Gorjestani, S., Woo, G., Nguyen, A. V., Figueiredo, C. C., Foubert, P., et al. (2016) · Nature · doi:10.1038/nature19834 · Cited by 1,173
T-cell exhaustion in the tumor microenvironment
Jiang, Y., Li, Y., & Zhu, B. (2015) · Cell Death & Disease · doi:10.1038/cddis.2015.162 · Cited by 1,157
Self-citationDynamics of the immune reaction to pancreatic cancer from inception to invasion
Clark, C. E., Hingorani, S. R., Mick, R., Combs, C., Tuveson, D. A., & Vonderheide, R. H. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0175 · Cited by 990
Quezada, S. A., Simpson, T. R., Peggs, K. S., Merghoub, T., Vider, J., Fan, X., Blasberg, R., Yagita, H., Muranski, P., Antony, P. A., et al. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20091918 · Cited by 898 · cited 1×
“CD4+ T cells may also acquire cytotoxic activity in vivo as seen in some melanomas (47, 48), and can play a role in generating and maintaining memory CD8+ T cells (49, 50).”
BackgroundImmune cell infiltration as an indicator of the immune microenvironment of pancreatic cancer
Ino, Y., Yamazaki-Itoh, R., Shimada, K., Iwasaki, M., Kosuge, T., Kanai, Y., & Hiraoka, N. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.32 · Cited by 849
Ene–Obong, A., Clear, A. J., Watt, J., Wang, J., Fatah, R., Riches, J. C., Marshall, J. F., Chin–Aleong, J., Chelala, C., Gribben, J. G., et al. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.07.025 · Cited by 579
Fukunaga, A., Miyamoto, M., Cho, Y., Murakami, S., Kawarada, Y., Oshikiri, T., Kato, K., Kurokawa, T., Suzuoki, M., Nakakubo, Y., et al. (2004) · Pancreas · doi:10.1097/00006676-200401000-00023 · Cited by 532
Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer
Ali, K., Soond, D. R., Piñeiro, R., Hagemann, T., Pearce, W., Lim, E. L., Bouabe, H., Scudamore, C. L., Hancox, T., Maecker, H., et al. (2014) · Nature · doi:10.1038/nature13444 · Cited by 529
EGF Receptor Is Required for KRAS-Induced Pancreatic Tumorigenesis
Ardito, C. M., Grüner, B. M., Takeuchi, K. K., Lubeseder-Martellato, C., Teichmann, N., Mazur, P. K., DelGiorno, K. E., Carpenter, E. S., Halbrook, C. J., Hall, J. C., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.07.024 · Cited by 517
Naive tumor-specific CD4+ T cells differentiated in vivo eradicate established melanoma
Xie, Y., Akpinarli, A., Maris, C., Hipkiss, E. L., Lane, M., Kwon, E.-K. M., Muranski, P., Restifo, N. P., & Antony, P. A. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20091921 · Cited by 457
Molecular Mechanisms of IFN-γ to Up-Regulate MHC Class I Antigen Processing and Presentation
Zhou, F. (2009) · International Reviews of Immunology · doi:10.1080/08830180902978120 · Cited by 456
Bos, R., & Sherman, L. A. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1322 · Cited by 443
Longati, P., Jia, X., Eimer, J., Wagman, A., Witt, M.-R., Rehnmark, S., Verbeke, C., Toftgård, R., Löhr, M., & Heuchel, R. L. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-95 · Cited by 394
Eser, S., Reiff, N., Messer, M., Seidler, B., Gottschalk, K., Dobler, M., Hieber, M., Arbeiter, A., Klein, S., Kong, B., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.01.023 · Cited by 360
Tumor-Specific CD4+ T Cells Have a Major “Post-Licensing” Role in CTL Mediated Anti-Tumor Immunity
Marzo, A. L., Kinnear, B. F., Lake, R. A., Frelinger, J. J., Collins, E. J., Robinson, B. W. S., & Scott, B. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.11.6047 · Cited by 334
Macrophage PI3Kγ Drives Pancreatic Ductal Adenocarcinoma Progression
Kaneda, M. M., Cappello, P., Nguyen, A. V., Ralainirina, N., Hardamon, C. R., Foubert, P., Schmid, M. C., Sun, P., Mose, E., Bouvet, M., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1346 · Cited by 326
PI3K inhibitors in inflammation, autoimmunity and cancer
Stark, A.-K., Sriskantharajah, S., Hessel, E. M., & Okkenhaug, K. (2015) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2015.05.017 · Cited by 285
Phosphoinositide 3-kinase (PI3K) pathway inhibitors in solid tumors: From laboratory to patients
Janku, F. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.07.005 · Cited by 243
Control of T-Cell–Mediated Immune Response by HLA Class I in Human Pancreatic Carcinoma
Ryschich, E., Nötzel, T., Hinz, U., Autschbach, F., Ferguson, J., Simon, I., Weitz, J., Fröhlich, B., Klar, E., Büchler, M. W., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.498.11.2 · Cited by 212
KRAS Allelic Imbalance Enhances Fitness and Modulates MAP Kinase Dependence in Cancer
Burgess, M. R., Hwang, E., Mroue, R., Bielski, C. M., Wandler, A. M., Huang, B. J., Firestone, A. J., Young, A., Lacap, J. A., Crocker, L., et al. (2017) · Cell · doi:10.1016/j.cell.2017.01.020 · Cited by 183
Molecular Pathology of Pancreatic Cancer
Wood, L. D., Adsay, N. V., & Hruban, R. H. (2013) · Molecular Surgical Pathology · doi:10.1007/978-1-4614-4900-3_2 · Cited by 182
Kinase Regulation of Human MHC Class I Molecule Expression on Cancer Cells
Brea, E. J., Oh, C. Y., Manchado, E., Budhu, S., Gejman, R. S., Mo, G., Mondello, P., Han, J. E., Jarvis, C. A., Ulmert, D., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0177 · Cited by 173
Manipulation of costimulatory signals to enhance antitumor T-cell responses
Allison, J. P., Hurwitz, A. A., & Leach, D. R. (1995) · Current Opinion in Immunology · doi:10.1016/0952-7915(95)80077-8 · Cited by 171
Wong, S. B. J., Bos, R., & Sherman, L. A. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.5.3122 · Cited by 147
Analysis of PD1, PDL1, PDL2 expression and T cells infiltration in 1014 gastric cancer patients
Xing, X., Guo, J., Ding, G., Li, B., Dong, B., Feng, Q., Li, S., Zhang, J., Ying, X., Cheng, X., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2017.1356144 · Cited by 145
Combined MEK and PI3K Inhibition in a Mouse Model of Pancreatic Cancer
Alagesan, B., Contino, G., Guimaraes, A. R., Corcoran, R. B., Deshpande, V., Wojtkiewicz, G. R., Hezel, A. F., Wong, K.-K., Loda, M., Weissleder, R., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1591 · Cited by 144
Low Surface Expression of B7-1 (CD80) Is an Immunoescape Mechanism of Colon Carcinoma
Tirapu, I., Huarte, E., Guiducci, C., Arina, A., Zaratiegui, M., Murillo, O., Gonzalez, A., Berasain, C., Berraondo, P., Fortes, P., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-1681 · Cited by 141
Metastatic progression is associated with dynamic changes in the local microenvironment
Aiello, N. M., Bajor, D. L., Norgard, R. J., Sahmoud, A., Bhagwat, N., Pham, M. N., Cornish, T. C., Iacobuzio-Donahue, C. A., Vonderheide, R. H., & Stanger, B. Z. (2016) · Nature Communications · doi:10.1038/ncomms12819 · Cited by 136
PI3K Regulation of RAC1 Is Required for KRAS-Induced Pancreatic Tumorigenesis in Mice
Wu, C.-Y. C., Carpenter, E. S., Takeuchi, K. K., Halbrook, C. J., Peverley, L. V., Bien, H., Hall, J. C., DelGiorno, K. E., Pal, D., Song, Y., et al. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.08.032 · Cited by 135
Self-citationBaer, R., Cintas, C., Dufresne, M., Cassant-Sourdy, S., Schönhuber, N., Planque, L., Lulka, H., Couderc, B., Bousquet, C., Garmy-Susini, B., et al. (2014) · Genes & Development · doi:10.1101/gad.249409.114 · Cited by 129
The Molecular Pathology of Pancreatic Cancer
Lemoine, N. R. (1993) · Springer eBooks · doi:10.1007/978-3-642-77437-9_63 · Cited by 123
Shibuya, K. C., Goel, V. K., Xiong, W., Sham, J. G., Pollack, S. M., Leahy, A. M., Whiting, S. H., Yeh, M. M., Yee, C., Riddell, S. R., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0096565 · Cited by 119
Park, I. A., Hwang, S.-H., Song, I. H., Heo, S.-H., Kim, Y.-A., Bang, W. S., Park, H. S., Lee, M., Gong, G., & Lee, H. J. (2017) · PLOS ONE · doi:10.1371/journal.pone.0182786 · Cited by 119
Pandha, H., Rigg, A., John, J., & Lemoine, N. (2007) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.2006.03289.x · Cited by 113
Swann, S. A., Williams, M., Story, C. M., Bobbitt, K. R., Fleis, R. I., & Collins, K. L. (2001) · Virology · doi:10.1006/viro.2000.0816 · Cited by 107
CTLA-4/CD80 pathway regulates T cell infiltration into pancreatic cancer
Bengsch, F., Knoblock, D. M., Liu, A., McAllister, F., & Beatty, G. L. (2017) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-017-2053-4 · Cited by 105
Murthy, D., Attri, K. S., & Singh, P. K. (2018) · Frontiers in Physiology · doi:10.3389/fphys.2018.00335 · Cited by 104
Key Role of Phosphoinositide 3-Kinase Class IB in Pancreatic Cancer
Edling, C. E., Selvaggi, F., Buus, R., Maffucci, T., Di Sebastiano, P., Friess, H., Innocenti, P., Kocher, H. M., & Falasca, M. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1210 · Cited by 102
Tassi, E., Gavazzi, F., Albarello, L., Senyukov, V., Longhi, R., Dellabona, P., Doglioni, C., Braga, M., Di Carlo, V., & Protti, M. P. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.9.6595 · Cited by 102
Qiu, W., Sahin, F., Iacobuzio-Donahue, C. A., Garcia-Carracedo, D., Wang, W. M., Kuo, C.-Y., Chen, D., Arking, D. E., Lowy, A. M., Hruban, R. H., et al. (2011) · Oncotarget · doi:10.18632/oncotarget.357 · Cited by 99
Lohneis, P., Sinn, M., Bischoff, S., Jühling, A., Pelzer, U., Wisłocka, L., Bahra, M., Sinn, B. V., Denkert, C., Oettle, H., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.06.016 · Cited by 95
Implication of PI3K/Akt pathway in pancreatic cancer: When PI3K isoforms matter?
Baer, R., Cintas, C., Therville, N., & Guillermet‐Guibert, J. (2015) · Advances in Biological Regulation · doi:10.1016/j.jbior.2015.05.001 · Cited by 90
Xie, R., Cheng, M., Li, M., Xiong, X., Daadi, M. M., Sapolsky, R. M., & Zhao, H. (2013) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2013.132 · Cited by 86
Sennepin, A., Charpentier, S., Normand, T., Sarré, C., Legrand, A., & Mollet, L. (2009) · Analytical Biochemistry · doi:10.1016/j.ab.2009.06.004 · Cited by 84
Incomplete Differentiation of Antigen-Specific CD8 T Cells in Tumor-Draining Lymph Nodes
Hargadon, K. M., Brinkman, C. C., Sheasley-O’Neill, S. L., Nichols, L. A., Bullock, T. N. J., & Engelhard, V. H. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.9.6081 · Cited by 74
Roy, I., McAllister, D. M., Gorse, E., Dixon, K., Piper, C. T., Zimmerman, N. P., Getschman, A. E., Tsai, S., Engle, D. D., Evans, D. B., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2645 · Cited by 74
Redundancy of Direct Priming and Cross-Priming in Tumor-Specific CD8+ T Cell Responses
Wolkers, M. C., Stoetter, G., Vyth-Dreese, F. A., & Schumacher, T. N. M. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.7.3577 · Cited by 72
Kras mutant genetically engineered mouse models of human cancers are genomically heterogeneous
Chung, W.-J., Daemen, A., Cheng, J. H., Long, J. E., Cooper, J. E., Wang, B.-E., Tran, C., Singh, M., Gnad, F., Modrusan, Z., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1708391114 · Cited by 63
Judge, S. M., Deyhle, M. R., Neyroud, D., Nosacka, R. L., D’Lugos, A. C., Cameron, M. E., Vohra, R., Smuder, A. J., Roberts, B. M., Callaway, C. S., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-1558 · Cited by 57
Pham, K., Delitto, D., Knowlton, A. E., Hartlage, E. R., Madhavan, R., Gonzalo, D. H., Thomas, R. M., Behrns, K. E., George, T. J., Hughes, S. J., et al. (2016) · The American Journal of Pathology · doi:10.1016/j.ajpath.2016.02.009 · Cited by 46
Self-citationErratum: Corrigendum: PI3Kγ is a molecular switch that controls immune suppression
Kaneda, M. M., Messer, K. S., Ralainirina, N., Li, H., Leem, C. J., Gorjestani, S., Woo, G., Nguyen, A. V., Figueiredo, C. C., Foubert, P., et al. (2016) · Nature · doi:10.1038/nature21026 · Cited by 46
Pützer, B. M., Rödicker, F., Hitt, M., Stiewe, T., & Esche, H. (2002) · Molecular Therapy · doi:10.1006/mthe.2002.0570 · Cited by 42
Yu, C.-C., Qiu, W., Juang, C. S., Mansukhani, M. M., Halmos, B., & Su, G. H. (2017) · Cancer Letters · doi:10.1016/j.canlet.2016.10.013 · Cited by 41
Surgical options in the management of pancreatic cancer.
Hackert, T., Büchler, M. W., & Werner, J. (2009) · PubMed · Cited by 40
Durrant, L., Ballantyne, K. C., Armitage, N. C. M., Robins, R. A., MARKSMAN, R. A., Hardcastle, J. D., & Baldwin, R. (1987) · British Journal of Cancer · doi:10.1038/bjc.1987.218 · Cited by 37
Modulation of HLA-DR Expression in Epithelial Cells by Interleukin 1 and Estradiol-17β*
TABIBZADEH, S. S., Sivarajah, A., Carpenter, D. C., Ohlsson‐Wilhelm, B. M., & SATYASWAROOP, P. G. (1990) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-71-3-740 · Cited by 36
内山, 美., Usami, N., Kondo, M., Mori, S., Ito, M., Ito, G., Yoshioka, H., Imaizumi, M., Ueda, Y., Takahashi, M., et al. (2003) · International Journal of Cancer · doi:10.1002/ijc.11493 · Cited by 27
Ekkirala, C. R., Cappello, P., Accolla, R. S., Giovarelli, M., Romero, I., Garrido, C., Garcia-Lora, A. M., & Novelli, F. (2014) · Pancreas · doi:10.1097/mpa.0000000000000160 · Cited by 18
Li, K., Baird, M. A., Yang, J., Jackson, C., Ronchese, F., & Young, S. L. (2016) · Clinical & Translational Immunology · doi:10.1038/cti.2016.46 · Cited by 18
Ali, K., Soond, D. R., Piñeiro, R., Hagemann, T., Pearce, W. P., Lim, E. L., Bouabe, H., Scudamore, C. L., Hancox, T. C., Maecker, H. L., et al. (2016) · Nature · doi:10.1038/nature17641 · Cited by 7
Thomas, G. R., & Wen, J. (2006) · PubMed · Cited by 6
Cited by
Wang, S., Zheng, Y., Yang, F., Zhu, L., Zhu, X.-Q., Wang, Z.-F., Wu, X.-L., Zhou, C.-H., Yan, J.-Y., Hu, B.-Y., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00659-4 · Cited by 369
Antitumour immunity regulated by aberrant ERBB family signalling
Kumagai, S., Koyama, S., & Nishikawa, H. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-020-00322-0 · Cited by 278
Targeting MHC-I molecules for cancer: function, mechanism, and therapeutic prospects
Wu, X., Li, T., Jiang, R., Yang, X., Guo, H., & Yang, R. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01899-4 · Cited by 223
“Sivaram et al. have shown an inverse relationship between the PI3K/AKT pathway and MHCI expression in pancreatic cancer, leading to immune evasion [71].”
BackgroundImmunomodulation by targeted anticancer agents
Petroni, G., Buqué, A., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.11.009 · Cited by 212
Deregulation of HLA-I in cancer and its central importance for immunotherapy
Hazini, A., Fisher, K., & Seymour, L. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002899 · Cited by 203
Metadata
- Authors
- Sivaram, N., McLaughlin, P. A., Han, H. V., Petrenko, O., Jiang, Y.-P., Ballou, L. M., Pham, K., Liu, C., van der Velden, A. W. M., & Lin, R. Z.
- Affiliations
- Stony Brook University (US)
- Rutgers, The State University of New Jersey (US)
- Northport VA Medical Center (US)
- Corresponding author
- Lin, Richard Z.
- Venue
- Journal of Clinical Investigation
- Published
- 2019-07-15
- Volume
- 129
- Issue
- 8
- Pages
- 3264-3276
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- PMC
- PMC6668699
- OpenAlex
- W2945115405
- Cited by
- 78
- References
- 71
- Citations by year
- 2026: 4 · 2025: 11 · 2024: 11 · 2023: 18 · 2022: 10 · 2021: 15 · 2020: 7 · 2019: 2
- FWCI
- 3.55
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Clinical Investigation (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- U.S. Department of Veterans Affairs (BX004083)
- National Cancer Institute (CA194836)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK108989)
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Keywords
- PIK3CA, Akt signaling, pancreatic cancer, tumor immunogenicity, tumor-infiltrating T cells, KRAS G12D, MHC class I expression, CD80, T cell surveillance, adoptive T cell therapy, cancer immunotherapy, tumor immunosuppression
- MeSH terms
- Animals, Humans, Neoplasms, Experimental, Pancreatic Neoplasms, T-Lymphocytes, Histocompatibility Antigens Class I, Signal Transduction, Lymphocytes, Tumor-Infiltrating, Mice, SCID, B7-1 Antigen, Mice, Knockout, Adoptive Transfer, Xenograft Model Antitumor Assays, Cell Line, Tumor, Proto-Oncogene Proteins c-akt, Mice, Class I Phosphatidylinositol 3-Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.